The program committee is currently finalizing this year’s program, which promises to be one of our finest. Please check back often for updates on the scientific program, accreditation and other meeting-related information. To register early for the meeting, please click here:

MESSAGE FROM THE PROGRAM CHAIRS

Stephen A. Boorjian, MD R. Houston Thompson, MD

On behalf of the Department of Urology Faculty at Mayo Clinic, we would like to invite you to Reviews in Urology. This week-long postgraduate course, which will incorporate interactive discussions throughout, will provide a comprehensive update on urology from Mayo Clinic faculty at all three campus sites, as well as from a distinguished group of invited colleagues. Attendees can also enjoy the beauty that the Big Island in Hawaii has to offer. Nowhere else in the world will you fi nd such diverse natural beauty, including pristine rain forests, lava deserts, world-class beaches, snow-covered mountains, an active volcano and dazzling sunsets. In addition, there is available just about every outdoor activity imaginable, from nature hikes through the rain forest to world-class golfi ng and deep sea fi shing. We hope that you can join us in what promises to be a comfortable stay amidst delightful warm weather. R. Houston Thompson, MD Stephen A. Boorjian, MD

EVENING FUNCTIONS

One ticket to each evening function is included in your registration fee.

Welcome Reception
Date: Monday, February 6, 2012
Time: 6:30 p.m. – 8:30 p.m.
Location: Poolside
Attire: Resort Casual*
Cost: One ticket included in attendee and spouse/guest registrations. Additional tickets for adults $75.00 and children are complimentary.
Enjoy an evening poolside with your colleagues as we taste some of Hawaii’s fabulous cuisine and are entertained by local musicians.

Farewell Banquet
Date: Thursday, February 9, 2012
Time: 7:00 p.m. – 10:00 p.m.
Location: Makai Salon
Attire: Evening Resort**
Cost: One ticket included in attendee and spouse/guest registrations. Additional tickets for adults $95.00 and children are complimentary.
Say farewell to your new friends and colleagues as we enjoy a buffet created by the award-winning chefs at the Hapuna Beach Prince Hotel.

*Resort Casual Attire: For women, dress in a nice collared shirt with khakis, or a sundress with casual heels or dressy sandals. For men, a collared or polo shirt with linen pants or chinos are appropriate. Classic knits or pullovers can be worn and footwear should be flat shoes such as loafers.

**Evening Resort Attire: For women, choose an elegant dress or evening gown with dress shoes. For men, collared shirts with dress slacks and dress shoes are appropriate.

HOTEL INFORMATION
Hapuna Beach Prince Hotel
62-100 Kauna’oa Drive
Kohala Coast, Hawaii
Main: (808) 880-1111
Fax: (808) 880-3142
Website: www.princeresortshawaii.com

Room Rate (Te rrace/Partial Ocean): $149/night
Hotel Deadline: December 30, 2011
Reservation Line: (866) 774-6236

Room Rate
The Reviews in Urology has reserved a block of rooms at the Hapuna Beach Prince Hotel at the discounted rates listed below:

Terrace/Partial Ocean: $149
Ocean View: $179
Premium Ocean: $189
Ocean Front: $229
Ocean Suite: $325

Above rates are for single or double occupancy, and are subject to applicable occupancy and sales tax.

Hotel Deadline
The deadline to receive the conference group rate is December 30, 2011. We encourage you to make your reservation early, as the hotel and discount block may sellout before this date. After this date, reservations will be accepted on a space-available basis and higher rates may apply.

Reservations
Attendees are responsible for making their reservations by calling the hotel at ( 866) 774-6236 . Please reference the Mayo Clinic Reviews in Urology to receive the discounted rate.

Hotel Deposit & Cancellation Policy
A deposit equal to one night’s stay is required to hold a reservation. Any and all individual cancellations between thirty (30) days and fourteen (14) days prior to arrival will be subject to a cancellation fee of two (2) nights’ room charge.

Individual cancellations within fourteen (14) days of arrival and any no shows will be assessed a three (3) nights’ room charge.

TRAVEL & TRANSPORTATION

Airport Information
Kona International Airport at Keahole (KOA) is approximately 25 miles from the Hapuna Beach Prince Hotel or 4 0 minutes by car.

Taxi Cab Services
Taxi service at the Kona International Airport is provided by various independent companies outside baggage claim areas A and B.

Shuttle Service
The Hapuna Beach Prince Hotel can arrange round-trip ground transportation from the Kona International Airport when reservations are made in advance. Please contact the concierge at least one week prior to your arrival date at (808) 880-1111.

Rental Car Information
Avis Rent-A-Car is the official rental car company for the conference . For reservations, please call (800) 331-1600, and use the code “J901055” to receive the discounted rates.

Parking
The conference is happy to offer complimentary self-parking at the Hapuna Beach Prince Hotel . The hotel also offers valet parking ($20 per day). Please note that rates are subject to change.

CHILDCARE SERVICES

Malihini Keiki Care
Sitting service
(808) 331-2909

Malihini Keiki Care offers hotel babysitting to accommodate guests. They select nannies based on your needs to come to your location to care for infants, toddlers and children. The base rate is $18.00 per hour for one child. There are additional charges for siblings, children from a separate family, service between the hours of 8 p.m. and midnight, service for more than an 8-hour period, travel fees and requests with less than 5 hours notice. All nannies:

• Are trained in infant and child CPR
• Have passed a criminal clearance
• Have medical and TB clearance
• Have attended required training
• Have submitted two references
• Have previous childcare experience
• Have picture identification and committed to service

For additional information or to make a reservation, please call (808) 331-2909 or email mkcare@hawaii.rr.com. Additional information can also be found on the website at www.mkcare.com.

ADDITIONAL REGISTRATION INFORMATION
The conference manages registration for the Annual Meeting. Please call the office at (847) 517-7225 if you have any questions.

Registration Includes:

• 5 Days of Continental Breakfasts
• Scientific Sessions
• One Welcome Reception ticket
• One Farewell Banquet ticket

Spouse/Guest Registration Includes:

• 5 Days of Continental Breakfasts
• One Welcome Reception ticket
• One Farewell Banquet ticket  

Early Registration Deadline
Meeting registration forms must be received by the conference by 12/30/11 to receive the discounted early registration rate. All forms received after this deadline will be assessed the regular registration fee.  

Registration Cancellation & Refund Policy
Registration refund requests must be submitted in writing to the conference by 12/30/11. All refund requests will be subject to a $100 processing fee. No refunds will be made after 12/30/11. 

Mayo School of Continuous Professional Development reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event Mayo School of Continuous Professional Development must cancel or postpone this course, Mayo School of Continuous Professional Development will refund the registration fee, but is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.

Pre-Registrants
Conference pre-registrants will receive a complete registration packet on-site at the registration/information desk located off the hotel lobby. The packet will include badges, social tickets, and general meeting information.

Disclaimer Statement
Statements, opinions and results of studies contained in the program and abstracts are those of the presenters/authors and do not reflect the policy or position of the conference nor does the conference provide any warranty as to their accuracy or reliability.

Special Needs
For accommodations on the basis of disability or special dietary needs, please call (847) 517-7225.

Questions
Please feel free to contact the Mayo Clinic Reviews in Urology by:
Phone: (847) 517-7225
Fax: (847) 517-7229
Email: hawaii2012@wjweiser.com
Website: www.wjweiser.com  

CME Accreditation Statement/Educational Needs & Objectives

Accreditation Statement
College of Medicine, Mayo Clinic, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

College of Medicine, Mayo Clinic designates this live activity for a maximum of 25.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosure

Needs Assessment
The diagnosis and management of many urologic diseases have been dramatically influenced by recent medical, surgical and technological advances. One of the greatest challenges for the practicing urologist is to stay current with the numerous dynamic changes in the field of urology. A nationally acclaimed faculty has been assembled to provide this update with presentations on localized and locally advanced prostate cancer, sexual dysfunction and infertility, multidisciplinary management of bladder cancer, novel surgical treatment of BPH, kidney and testis cancer, overactive bladder and treatment of the failed sling and artificial sphincter.

Prostate cancer is the most common non-cutaneous cancer in men in the US, and the second leading cause of male cancer mortality. Intense research has focused on the low-risk patient (who is likely being over treated) and the high-risk patient (who is likely being undertreated). However, the majority of patients treated today have intermediate risk disease. Patients and physicians continue to struggle with the optimal management of these patients. An understanding of the advantages and disadvantages of specific treatments allows optimal counseling of this patient population.

Dramatic advances in the surgical practice of sexual medicine have occurred over the past decade. Post-graduate surgeons have few opportunities to learn new techniques and appreciate the outcomes of their current techniques in the broader population. The program will provide an update on advances in surgical approaches to erectile dysfunction. Additionally, the program will provide an update on PDE5-Inhibitors with a focus on both FDA-approved formulations and internationally tested and approved formulations. The administration, efficacy and safety of these approved products will be compared to “boot-legged” pharmaceuticals in the international market place.

While renal preservation using partial nephrectomy has gained acceptance over the past decade and now is the treatment of choice for small peripheral lesions, the management of large renal masses (>7cm) is not clear. Elective partial nephrectomy will preserve renal function but at the potential cost of increased risk of tumor recurrence. An understanding of the costs and benefits of elective partial nephrectomy for larger renal masses is critical to the management of these patients. A second trend in renal urologic oncology is the increased utilization of robotic and laparoscopic partial nephrectomy. Clinicians need to understand the biology and clinical implications of warm ischemia, to allow proper selection of patients and techniques for treatment of renal masses.

Germ cell tumors of the testicle are the most common solid tumor malignancies in young healthy men. The majority of patients who present with seminoma have no evidence of metastatic disease (clinical stage I). While the treatment options for these patients have historically included observation, radiation therapy and chemotherapy, increasing data has emerged on the long term risks of cardiovascular disease and second malignancies in testicular cancer survivors, particularly those who have received treatment. At the same time, non-seminoma presents with metastatic disease in 70% of patients and the cure rate with cisplatin based chemotherapy is dependent on the extent and sites of disease and serum tumor marker elevation. The role of surgery versus observation for the subcentimeter residual retroperitoneal mass remains highly controversial and insight into the advantages and disadvantages of each option are critical.

Bladder cancer is the second most common genitourinary cancer in males and the fourth most common in females. There will be an estimated 71,000 new cases and 15,000 deaths from bladder cancer in 2010. Approximately 70% of the time, patients present with non-muscle invasive disease. Of those, 70% are Ta lesions, 20% T1, and 10% carcinoma in situ (CIS). While intravesical therapy is a recommended approach for patients with high-risk non-muscle invasive tumors, the optimal management for patients with recurrent high grade non-muscle invasive disease continues to be debated. Meanwhile, muscle invasive cancer accounts for the remainder of patients and 80% of these patients present de novo with invasive cancer as their first manifestation of the disease. Practitioners need to be aware of the non-radical cystectomy options for managing muscle invasive bladder cancer with a focus on the proper selection of patients for the various treatment modalities.

It has become increasingly difficult for the practicing urologist to stay abreast with the many dynamic changes in the treatment of BPH. Moreover, given the prevalence of BPH in the aging male population, practitioners need to be aware of the more complex situations that will be encountered which may affect BPH management, including bladder stones and poor baseline bladder function.

Educational Objectives
Following participation in this program, attendees should be able to:

• Describe the current controversy surrounding PSA screening, and apply an evidence-based approach to future PSA screening in clinical practice.
• Evaluate recent advances in systemic therapy for advanced prostate carcinoma.
• Identify the roles of adjuvant and salvage therapies for patients with biochemical recurrence after radical prostatectomy.
• Recognize treatment outcomes after various management strategies for patients with high-risk prostate cancer.
• Assess recent data regarding the management of post-prostatectomy erectile dysfunction, and be able to critically evaluate reported results to date.
• Identify hypogonadism as a medical condition, and determine appropriate therapy to address patient needs by differentiating between the currently available testosterone formulations.
• Recognize the various management strategies for Peyronie’s Disease, and determine the factors which should be incorporated in order to individualize treatment approach.
• Describe the techniques and complications associated with vasectomy.
• Identify treatment options and expected outcomes for varicocelectomy.
• Recognize the diagnostic work-up for the azoospermic male.
• Describe the mechanisms of injury caused by renal ischemia.
• Assess the risks and benefits of partial nephrectomy for renal masses.
• Recognize the role of cytoreductive nephrectomy in the targeted therapy era.
• Describe the treatment options for patients with clinical stage I seminoma, and discuss the treatment-related toxicities which have been identified with each management strategy.
• Recognize the treatment algorithm for patients with residual masses after chemotherapy for nonseminomatous germ cell testicular tumors.
• Create strategies for the medical and surgical management of renal and ureteral stones based on AUA guidelines.
• Recognize the options for the management of patients with urolithiasis in the setting of pregnancy.
• Describe BCG-refractory disease and understand the options for management available for these patients, including the risks and benefits of each approach.
• Employ a state of science look at the evidence supporting peri-operative chemotherapy as part of a multimodality treatment for invasive bladder cancer.
• Identify non-surgical options for managing muscle invasive bladder cancer with a focus on the proper selection of patients for the various treatment modalities.
• Recognize the various medical and surgical options for BPH, and be able to evaluate patients for pharmacologic treatments vs. minimally-invasive therapies of BPH.
• Employ appropriate candidate selection for Holmium Laser Enucleation of the Prostate (HoLEP), based on an understanding of the technique, technical challenges to the procedure and potential risks and benefits.
• Create strategies for the management of BPH in the setting of various concomitant bladder conditions, including stones and poor contractility.
• Review the diagnosis and treatment options for OAB, including oral therapies and long-term, localized treatment for patients whose OAB is refractory to oral therapy.
• Identify treatment options for the failed/obstructed transvaginal sling.
• Evaluate the best procedure for male urinary incontinence.
• Explain management and treatment options for failed sling or artificial sphincter procedures.

2012 Exhibitors	Platinum Level Partner		Gold Level Partner
American Medical Systems, Inc. Astellas Pharma Coloplast Cook Medical Dendreon Corporation Karl Storz Prometheus Laboratories Inc.

Registration/Information Desk Open
Location: Pre Makai

Session 1: Localized Prostate Cancer
Moderator: Stephen A. Boorjian, MD

Introduction
R. Houston Thompson, MD
Stephen A. Boorjian, MD

PSA Screening: Whom, When, and How Often?
Anthony V. D’Amico, MD, PhD

Surgical Technique for Robot Prostatectomy – Lessons Learned
Matthew T. Gettman, MD

Long-Term Outcomes with Open Radical Prostatectomy
R. Jeffrey Karnes, MD

The Future Role of Radical Prostatectomy for Treatment of Prostate Cancer
Joseph A. Smith, Jr., MD

Radiation for Low-Risk Prostate Cancer
Anthony V. D’Amico, MD, PhD

Challenging Robotic Prostatectomy Issues
Igor Frank, MD

Current Role of Chemo-Prevention and Active Surveillance in Prostate Cancer
Todd C. Igel, MD

Case Presentations and Panel Discussion
Moderator:
Stephen A. Boorjian, MD

Panel:
Joseph A. Smith, Jr., MD
Matthew T. Gettman, MD
Igor Frank, MD
Anthony V. D’Amico, MD, PhD
R. Jeffrey Karnes, MD
Todd C. Igel, MD

Session 2: Sexual Dysfunction
Moderator: Lance A. Mynderse, MD

Latest in Management of Post-Prostatectomy Erectile Dysfunction
Ajay Nehra, MD

Testosterone Supplementation: Lessons Learned
Peter N. Schlegel, MD, FACS

Current Management of Peyronie’s Disease
Ajay Nehra, MD

Case Presentations and Panel Discussion
Moderator:
Lance A. Mynderse, MD

Panel Discussion:
Ajay Nehra, MD
Peter N. Schlegel, MD, FACS

Registration/Information Desk Open
Location: Pre Makai

Session 1: Advanced Prostate Cancer
Moderator: R. Jeffrey Karnes, MD

Radiation and Hormonal Therapy in the Management of Advanced Prostate Cancer
Anthony V. D’Amico, MD, PhD

Open Surgery for High-Risk Prostate Cancer
R. Jeffrey Karnes, MD

Robotic Surgery for High-Risk Prostate Cancer
Matthew T. Gettman, MD

Management of a Rising PSA after Definitive Local Treatment
Anthony V. D’Amico, MD, PhD

Optimal Management of Node-Positive Prostate Cancer
Stephen A. Boorjian, MD

Break
Location: Mauka Salon

Management of Hormone Refractory Prostate Cancer
Brian A. Costello, MD

Immunotherapeutic Horizons in Prostate Cancer
Eugene Kwon, MD

Case Presentations and Panel Discussion
Moderator:
R. Jeffrey Karnes, MD

Panel:
R. Jeffrey Karnes, MD
Matthew T. Gettman, MD
Brian A. Costello, MD
Anthony V. D’Amico, MD, PhD
Stephen A. Boorjian, MD
Eugene Kwon, MD

Session 2: Infertility
Moderator: Lance A. Mynderse, MD

Vasectomy: Practical Tips and What’s New

Peter N. Schlegel, MD, FACS

Current Management of Varicocele

Ajay Nehra, MD

Management of Azoospermia

Peter N. Schlegel, MD, FACS

Case Presentations and Panel Discussion
Moderator:
Lance A. Mynderse, MD

Panel Discussion:
Ajay Nehra, MD
Peter N. Schlegel, MD, FACS

Registration/Information Desk Open
Location: Pre Makai

Session 1: Kidney and Testis Cancer
Moderator: Bradley C. Leibovich, MD

Contemporary Use of Partial Nephrectomy and Implications of Ischemia
R. Houston Thompson, MD

Update on Percutaneous Ablation for Renal Masses
Thomas D. Atwell, MD

Surgical Management of Advanced Kidney Cancer
Bradley C. Leibovich, MD

Immunotherapy: What the Future Holds
Eugene Kwon, MD

Overview of Systemic Therapy for Advanced Renal Carcinoma
Brian A. Costello, MD

Contemporary Management of Testis Cancer
Stephen A. Boorjian, MD

Debate: Post-Chemotherapy RPLND: For All Patients?
Con: Bradley C. Leibovich, MD
Pro: R. Houston Thompson, MD

Case Presentations and Panel Discussion
Moderator:
Bradley C. Leibovich, MD

Panel:
Thomas D. Atwell, MD
Stephen A. Boorjian, MD
R. Houston Thompson, MD
Brian A. Costello, MD
Eugene Kwon, MD

Session 2: Urolithiasis
Moderator: Matthew T. Gettman, MD

Medical Management of Urolithiasis
Amy E. Krambeck, MD

Contemporary PCNL Management for Staghorn Calculi
Mitchell R. Humphreys, MD

Challenging Stone Situations: Pregnancy, Encrusted Stent and Beyond
Amy E. Krambeck, MD

Case Presentations and Panel Discussion
Moderator:
Matthew T. Gettman, MD

Panel Discussion:
Amy E. Krambeck, MD
Mitchell R. Humphreys, MD

Registration/Information Desk Open
Location: Pre Makai

Session 1: Bladder Cancer
Moderator: Igor Frank, MD

Management of BCG Refractory Bladder Cancer
Sam Chang, MD

Robotic Radical Cystectomy: Lessons Learned
Erik P. Castle, MD

Radical Cystectomy for Bladder Cancer — Will Minimally Invasive Surgery Take Over?
Joseph A. Smith, Jr., MD

Continent Urinary Diversions: Tips in Radical Cystectomy
Sam Chang, MD

Update on Tri-Modality Treatment for Invasive Bladder Cancer
Brian J. Davis, MD, PhD

Systemic Chemotherapy for Urothelial Carcinoma: When Should We Use It?
Brian A. Costello, MD

Pathologic Re-Review: When Should You Get a Second Opinion?
John C. Cheville, MD

Case Presentations and Panel Discussion
Moderator:
Igor Frank, MD

Panel:
Sam Chang, MD
Erik P. Castle, MD
Brian A. Costello, MD
John C. Cheville, MD
Brian J. Davis, MD, PhD
Joseph A. Smith, Jr., MD

Session 2: BPH
Moderator: Amy E. Krambeck, MD

Medical Management and Minimally Invasive Treatment of BPH: Future Directions
Lance A. Mynderse, MD

Learning Curve for HOLEP: Lessons Learned
Amy E. Krambeck, MD

Concomitant Issues When Managing BPH: Poor Contractility, Tumors, Elderly, Stones
Mitchell R. Humphreys, MD

Case Presentations and Panel Discussion
Moderator:
Amy E. Krambeck, MD

Panel Discussion:
Lance A. Mynderse, MD
Mitchell R. Humphreys, MD

Registration/Information Desk Open
Location: Pre Makai

Session 1: Urinary Incontinence
Moderators: Daniel S. Elliott, MD and Victor Nitti, MD

Overactive Bladder: Current Concepts and Management
Daniel S. Elliott, MD

How to Treat Persistent Incontinence After a Transvaginal Sling?
Victor Nitti, MD

Evaluation and Treatment of the Obstructed Sling Patient
Victor Nitti, MD

Vault Prolapse: Contemporary Options
Daniel S. Elliott, MD

Artificial Sphincter vs. Male Sling: Treatment Options for Male Incontinence
Victor Nitti, MD

How to Treat the Failed Male Sling Patient
Victor Nitti, MD

Evaluation and Treatment Options for the Failed AGUS
Daniel S. Elliott, MD

Case Presentations and Panel Discussion
Moderators:
Daniel S. Elliott, MD
Victor Nitti, MD

Panel:
Daniel S. Elliott, MD
Victor Nitti, MD

Session 2: Looking Ahead to the Future in Urology
Moderator: Lance A. Mynderse, MD

HEXVIX and CYSVIEW: Hype or Real?
Lance A. Mynderse, MD

PET Choline Imaging of Advanced Prostate Cancer
Eugene Kwon, MD

The Problem of Major Surgical Procedures in the Developing World
Joseph A. Smith, Jr., MD

Future Approaches to Minimally Invasive Surgery: From NOTES and Beyond
Matthew T. Gettman, MD